The system will perform 200 multiplexed pathogen ID tests or 40 AST tests in one eight-hour shift on a random access, fully automated benchtop instrument.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.